Sorry, you need to enable JavaScript to visit this website.
Skip to main content


Janssen Expands Research & Development Presence with Major Investment in South San Francisco

Jan 10, 2020
United States

NEW BRUNSWICK, NJ, January 10, 2020 — The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced a significant investment to expand the presence and capabilities of Janssen Research & Development, LLC, in the San Francisco Bay Area. Reflecting the significant impact of Janssen and its research and development strategic direction on the mission of innovation at Johnson & Johnson, this investment will support the leasing and construction of a state-of-the-art R&D facility in the global innovation center of South San Francisco, CA. Janssen BioPharma, Inc., executed the lease within the Healthpeak Properties, Inc., South San Francisco project at The Shore at Sierra Point, Brisbane, CA.

With this investment, Janssen will continue to enable world-class discovery, enhance collaboration opportunities with innovation partners and integrate data science in all aspects of research and development. Moreover, this expansion will allow Janssen to bridge key interdisciplinary capabilities, such as biology and data science, to fuel a step-change in how it creates medicines. San Francisco is consistently ranked among the top cities globally for biologics development and life sciences research. The area also leads the world in “bilingual” data science talent, namely those individuals who are conversant in both life sciences and technology.

“As a well-established global technology and entrepreneurial hub and home to a wide array of pharmaceutical and biotechnology companies, the South San Francisco Bay Area is an ideal location to expand our R&D capabilities and global footprint,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development. “Expanding our R&D presence in South San Francisco will better enable deep partnerships with biotechnology companies, universities and investors in the region. This is one important step to enable us to accelerate the growth of our portfolio of innovative products ultimately to deliver better health outcomes for patients around the world. We look forward to being an even greater contributor to and participant in one of the most vibrant scientific ecosystems in the world.”  

Janssen personnel at this new facility will focus on infectious and retinal diseases, data science and emerging modalities within discovery, product development and supply. The expanded facility is projected to more than double Janssen’s presence in South San Francisco and is anticipated to be fully operational in 2022, upon completion of construction.

About the Janssen Pharmaceutical Companies

At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at Follow us at @JanssenGlobal.

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.  Learn more at Follow us at @JNJNews.


Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding Johnson & Johnson’s investment to expand Janssen’s research and development presence and capabilities in the San Francisco Bay Area. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the investment may not be realized or may take longer to realize than expected; challenges inherent in new product development, including the uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2018, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the company’s most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. Neither the Janssen Pharmaceutical Companies nor Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments.

Media inquiries:
Paul Graves
Phone: 732-519-2674
Email: [email protected]

Investor Relations:
Lesley Fishman
Phone: 732-524-3922
Email: [email protected]